Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PanGenomic Health Inc - Vancouver, Canada-based precision health company - Pretax loss for the half-year to June 30 widens 20% to C$2.0 million from C$1.6 million a year prior, with both figures being the same for expenses of their respective half-years. Company highlights that it introduced in-clinic access to patient vitamin D assessments through the biomarker platform by its subsidiary MUJN Diagnostics Inc. Further, PanGenomic launched an e-commerce platform to market its proprietary natural herbal remedy information library.
Current stock price: C$0.030
12-month change: down 86%
Copyright 2023 Alliance News Ltd. All Rights Reserved.